Correction: The use of the CNIC-Polypill in real-life clinical practice: opportunities and challenges in patients at very high risk of atherosclerotic cardiovascular disease - expert panel meeting report.
作者信息
Grigorian-Shamagian Lilian, Coca Antonio, Morais Joao, Perez-Martinez Pablo
机构信息
Department of Cardiology, Hospital General Universitario Gregorio MarañónInstituto de Investigación Sanitaria Gregorio Marañón and Facultad de MedicinaUniversidad Complutense de Madrid, Madrid, Spain.
Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain.
出版信息
BMC Proc. 2023 Oct 12;17(1):27. doi: 10.1186/s12919-023-00279-6.
Abstract
摘要
相似文献
1
Correction: The use of the CNIC-Polypill in real-life clinical practice: opportunities and challenges in patients at very high risk of atherosclerotic cardiovascular disease - expert panel meeting report.更正：在现实临床实践中使用CNIC多效药丸：动脉粥样硬化性心血管疾病极高风险患者面临的机遇与挑战——专家小组会议报告
BMC Proc. 2023 Oct 12;17(1):27. doi: 10.1186/s12919-023-00279-6.
2
The use of the CNIC-Polypill in real-life clinical practice: opportunities and challenges in patients at very high risk of atherosclerotic cardiovascular disease - expert panel meeting report.CNIC复合制剂在实际临床实践中的应用：动脉粥样硬化性心血管疾病极高风险患者面临的机遇与挑战——专家小组会议报告
BMC Proc. 2023 Aug 17;17(Suppl 8):20. doi: 10.1186/s12919-023-00268-9.
3
The CNIC-Polypill reduces recurrent major cardiovascular events in real-life secondary prevention patients in Spain: The NEPTUNO study.CNIC-复方药在西班牙真实二级预防患者中降低复发性主要心血管事件：NEPTUNO 研究。
Int J Cardiol. 2022 Aug 15;361:116-123. doi: 10.1016/j.ijcard.2022.05.015. Epub 2022 May 13.
4
Cost-Effectiveness of the CNIC-Polypill Strategy Compared With Separate Monocomponents in Secondary Prevention of Cardiovascular and Cerebrovascular Disease in Portugal: The MERCURY Study.在葡萄牙心血管和脑血管疾病二级预防中，与单一成分药物分别使用相比，CNIC复方药丸策略的成本效益：MERCURY研究
J Health Econ Outcomes Res. 2022 Nov 22;9(2):134-146. doi: 10.36469/001c.39768. eCollection 2022.
5
Safety and efficacy of a cardiovascular polypill in people at high and very high risk without a previous cardiovascular event: the international VULCANO randomised clinical trial.心血管复方药在无既往心血管事件的高危和极高危人群中的安全性和疗效：国际 VULCANO 随机临床试验。
BMC Cardiovasc Disord. 2022 Dec 22;22(1):560. doi: 10.1186/s12872-022-03013-w.
6
Cost-effectiveness of the CNIC-Polypill versus separate monocomponents in cardiovascular secondary prevention in Spain.西班牙心血管二级预防中，CNIC 复方与单一成分药物的成本效益比较。
Rev Clin Esp (Barc). 2023 Aug-Sep;223(7):414-422. doi: 10.1016/j.rceng.2023.06.007. Epub 2023 Jun 21.
7
Clinical Effectiveness of the Cardiovascular Polypill in a Real-Life Setting in Patients with Cardiovascular Risk: The SORS Study.心血管多效药丸在心血管风险患者真实环境中的临床效果：SORS 研究。
Arch Med Res. 2019 Jan;50(1):31-40. doi: 10.1016/j.arcmed.2019.04.001. Epub 2019 Apr 19.
8
Reaching blood pressure guideline targets with the CNIC polypill in patients with a previous cardiovascular event in Mexico: a analysis of the SORS study.在墨西哥有既往心血管事件的患者中，使用 CNIC 复方药实现血压指南目标：SORS 研究分析。
Future Cardiol. 2020 Jan;16(1):53-60. doi: 10.2217/fca-2019-0075. Epub 2019 Dec 18.
9
The Fuster-CNIC-Ferrer Cardiovascular Polypill: a polypill for secondary cardiovascular prevention.福斯特-西班牙国家心血管研究中心-费雷尔心血管复方制剂：一种用于心血管疾病二级预防的复方制剂
Int J Cardiol. 2015 Dec;201 Suppl 1:S15-22. doi: 10.1016/S0167-5273(15)31028-7.
10
Pharmacodynamic study of the cardiovascular polypill. Is there any interaction among the monocomponents?心血管复方药的药效学研究。各单一组分之间是否存在相互作用？
Rev Esp Cardiol (Engl Ed). 2021 Jan;74(1):51-58. doi: 10.1016/j.rec.2019.11.008. Epub 2020 Jan 23.
本文引用的文献
1
The use of the CNIC-Polypill in real-life clinical practice: opportunities and challenges in patients at very high risk of atherosclerotic cardiovascular disease - expert panel meeting report.CNIC复合制剂在实际临床实践中的应用：动脉粥样硬化性心血管疾病极高风险患者面临的机遇与挑战——专家小组会议报告
BMC Proc. 2023 Aug 17;17(Suppl 8):20. doi: 10.1186/s12919-023-00268-9.
Zotero 插件